The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, reviewed the Kingdom of Saudi Arabia’s experience in supporting drug availability for patients and beneficiaries. He highlighted the role of an integrated digital infrastructure and the reliance on artificial intelligence technologies to ensure the success of the initiative. His remarks were delivered today, Tuesday, during his virtual participation at the parallel program at the National Defense College in the Sultanate of Oman, entitled, "Health Security: Reality and Aspiration."

Dr. Aljadhey highlighted the Kingdom’s exceptional efforts in drug availability, citing key initiatives such as the launch of the Drug Track and Trace System for Pharmaceutical Products (RSD). This system tracks and traces all registered human medicines, whether manufactured within the Kingdom or imported from abroad.

Concluding his remarks, Dr. Aljadhey emphasized that the Kingdom places health at the top of its priorities as a fundamental component of progress and development. He reiterated the Kingdom's commitment to achieving drug security to preserve human health and safety and to accomplish the objectives of the Health Sector Transformation Program, one of the core initiatives of Saudi Vision 2030.